Tags

Type your tag names separated by a space and hit enter

Pharmacodynamics of TNF-α inhibitors in psoriasis.
Expert Rev Clin Pharmacol 2011; 4(4):515-23ER

Abstract

Over the last two decades, research developments have revolutionized our understanding of the pathogenesis of psoriasis and of the contribution of several cytokines in the manifestation of the disease. The key role of TNF-α in the pathogenesis of psoriasis has been extensively studied and its therapeutic action, initially observed in experimental models, has been clinically translated into therapeutic agents with remarkable efficacy in the treatment of the disease. There are currently two classes of marketed biologic drugs that reduce TNF-α bioavailability and are used clinically in psoriasis: the soluble TNF-α receptor-Fc fusion protein (etanercept) and the anti-TNF-α monoclonal antibodies (adalimumab and infliximab). The present article reviews the pharmacodynamic properties of the three TNF-α inhibitors and discusses possible differences in their mode of action, clinical efficacy and safety profile.

Authors+Show Affiliations

Department of Dermatology, University of Athens, Andreas Sygros Hospital, Athens, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22114860

Citation

Vergou, Theognosia, et al. "Pharmacodynamics of TNF-α Inhibitors in Psoriasis." Expert Review of Clinical Pharmacology, vol. 4, no. 4, 2011, pp. 515-23.
Vergou T, Moustou AE, Sfikakis PP, et al. Pharmacodynamics of TNF-α inhibitors in psoriasis. Expert Rev Clin Pharmacol. 2011;4(4):515-23.
Vergou, T., Moustou, A. E., Sfikakis, P. P., Antoniou, C., & Stratigos, A. J. (2011). Pharmacodynamics of TNF-α inhibitors in psoriasis. Expert Review of Clinical Pharmacology, 4(4), pp. 515-23. doi:10.1586/ecp.11.28.
Vergou T, et al. Pharmacodynamics of TNF-α Inhibitors in Psoriasis. Expert Rev Clin Pharmacol. 2011;4(4):515-23. PubMed PMID: 22114860.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacodynamics of TNF-α inhibitors in psoriasis. AU - Vergou,Theognosia, AU - Moustou,Aikaterini-Evangelia, AU - Sfikakis,Petros P, AU - Antoniou,Christina, AU - Stratigos,Alexander J, PY - 2011/11/26/entrez PY - 2011/11/26/pubmed PY - 2012/9/5/medline SP - 515 EP - 23 JF - Expert review of clinical pharmacology JO - Expert Rev Clin Pharmacol VL - 4 IS - 4 N2 - Over the last two decades, research developments have revolutionized our understanding of the pathogenesis of psoriasis and of the contribution of several cytokines in the manifestation of the disease. The key role of TNF-α in the pathogenesis of psoriasis has been extensively studied and its therapeutic action, initially observed in experimental models, has been clinically translated into therapeutic agents with remarkable efficacy in the treatment of the disease. There are currently two classes of marketed biologic drugs that reduce TNF-α bioavailability and are used clinically in psoriasis: the soluble TNF-α receptor-Fc fusion protein (etanercept) and the anti-TNF-α monoclonal antibodies (adalimumab and infliximab). The present article reviews the pharmacodynamic properties of the three TNF-α inhibitors and discusses possible differences in their mode of action, clinical efficacy and safety profile. SN - 1751-2441 UR - https://www.unboundmedicine.com/medline/citation/22114860/Pharmacodynamics_of_TNF_α_inhibitors_in_psoriasis_ L2 - http://www.tandfonline.com/doi/full/10.1586/ecp.11.28 DB - PRIME DP - Unbound Medicine ER -